Rezolute shares are trading higher after the company announced the FDA has removed the partial clinical holds on RZ358.
Portfolio Pulse from Benzinga Newsdesk
Rezolute shares increased after the FDA lifted partial clinical holds on their drug RZ358.
September 09, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rezolute's stock price is likely to rise in the short term due to the FDA's decision to lift partial clinical holds on their drug RZ358, which is a positive regulatory development.
The FDA's removal of partial clinical holds on RZ358 is a significant regulatory milestone for Rezolute, likely boosting investor confidence and driving the stock price higher.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100